Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184609 | 0.93 | CYP1A2 (0.47) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL16184473 | 0.91 | CYP1A2 (0.49) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL14474177 | 0.90 | CYP1A2 (0.51) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL14474173 | 0.88 | MAPT (0.47) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL16184638 | 0.88 | CYP1A2 (0.48) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL16183494 | 0.88 | CYP1A2 (0.46) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL16184553 | 0.88 | MAPT (0.45) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL16184606 | 0.86 | LMNA (0.43) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL16184666 | 0.86 | ABCB1 (0.48) | CYP1A2MAPTLMNACYP3A4GMNN | |
| SCHEMBL14474236 | 0.86 | CYP1A2 (0.46) | CYP1A2MAPTLMNACYP3A4GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | CYP1A2 2971/4885MAPT 509/4885LMNA 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.